Shreyas Kalantri, MD (@KalantriShreyas) ranks #39 among US lung cancer KOLs on X in 2026, by engagement from fellow physicians. 3 physicians shared, quoted or replied to their posts this year. Most-discussed trials in 2026: KEYNOTE-B15 / EV-304, HARMONi-6, PROTEUS. CMS Open Payments lists $4,065 in 2025 general payments.
At a Glance
- 10 posts naming a trial in 2026
- 6 trials discussed by name
- Lung Cancer: US #39 · 3 physicians engaged
- CMS Open Payments lists $4,065 in 2025 general payments.
This Month
What Shreyas Kalantri, MD has posted in the last 30 days. Updated November 10, 2026.
No trial posts in the last 30 days.
Who Amplifies Shreyas Kalantri, MD
Physicians who reposted Shreyas Kalantri, MD’s trial posts most often in 2026.
2026 Rankings
| List | US rank | Global rank | Physicians engaged | Physician engagements | |
|---|---|---|---|---|---|
| Lung Cancer | #39 | — | 3 | 4 | Full ranking |
Trials Shreyas Kalantri, MD Discussed in 2026
| Trial | Posts | Rank among physicians posting | Latest |
|---|---|---|---|
| KEYNOTE-B15 / EV-304 | 3 | #29 of 44 | Mar 16, 2026 |
| HARMONi-6 | 2 | #12 of 74 | May 31, 2026 |
| PROTEUS | 2 | #31 of 56 | May 31, 2026 |
| LITESPARK-022 | 2 | #18 of 40 | Feb 28, 2026 |
| AMBASSADOR | 1 | #7 of 7 | May 29, 2026 |
| PEACE-3 | 1 | #9 of 10 | Mar 16, 2026 |
Shreyas Kalantri, MD on KEYNOTE-B15 / EV-304
Had a great time recording this Oncology Bytes episode with @ONCOassist reviewing key trials from @ASCO #GU26: • KEYNOTE-B15 in bladder cancer • Belzutifan trials in RCC • PEACE-3 in prostate cancer Always fun to discuss the studies shaping #GUOncology. https://t.co/eYoE91YDBQ
EV-304 | KEYNOTE-B15 Results #GU26 Perioperative EV + pembrolizumab significantly improved: • EFS: HR 0.53 (95% CI 0.41–0.70) 24-mo EFS 79.4% vs 66.2% • OS: HR 0.65 (0.48–0.89) 24-mo OS 86.9% vs 81.3% • pCR: 55.8% vs 32.5% (Δ 23.4%) Grade ≥3 TEAEs: 75.7% vs 67.2%. https://t.co/8F097Hjzi4
KEYNOTE-B15 / EV-304 #GU26 Phase 3 trial in cisplatin-eligible MIBC (N=808) Randomized 1:1: 🔹 Perioperative enfortumab vedotin + pembrolizumab (4 cycles neoadjuvant → RC+PLND → adjuvant EV+pembro) vs 🔸 Neoadjuvant cisplatin + gemcitabine → surgery → observation Primary https://t.co/g3XFSoCVYM
Shreyas Kalantri, MD on HARMONi-6
Love this slide from the Harmoni-6 discussion by Dr. Julie Brahmer. #asco26 https://t.co/MY83VxUop1
HARMONi-6 at #ASCO26: Ivonescimab + chemo improved OS vs tislelizumab + chemo in 1L advanced squamous NSCLC. mOS 27.9 vs 23.7 mo HR 0.66, 95% CI 0.50–0.87 p=0.0017 Important signal for dual VEGF/PD-1 targeting, with global HARMONi-3 ongoing. #LCSM #NSCLC @OncoAlert https://t.co/SMt8u5wC2N
Shreyas Kalantri, MD on PROTEUS
PROTEUS at #ASCO26: perioperative apalutamide + ADT with radical prostatectomy in high-risk localized/locally advanced prostate cancer met both primary endpoints. pCR/MRD: 8.9% vs 1.0% MFS: HR 0.80, 95% CI 0.67–0.96; p=0.02 @OncoAlert @urotoday https://t.co/DKKFJ8vcm7
Beyond the dual primary endpoints, PROTEUS showed downstream clinical benefit with APA + ADT: EFS: HR 0.71; p<0.0001 Time to distant metastases: HR 0.68; p=0.0002 Time to first subsequent therapy: HR 0.65, median 74.2 vs 41.5 months Adoption will hinge on patient selection, https://t.co/Ljgn2At5lP
Shreyas Kalantri, MD on LITESPARK-022
LITESPARK-022 Results #GU26 DFS improved with pembro + belzutifan vs pembro alone: HR 0.72 (95% CI 0.59–0.87), P=0.0003 Landmark DFS: • 12 mo: 91.9% vs 85.2% • 24 mo: 80.7% vs 73.7% • 30 mo: 75.8% vs 68.6% Interim OS: HR 0.78 (0.51–1.19), P=0.122 (not mature) @OncoAlert https://t.co/g2TiDm29L1
LITESPARK-022 #GU26 Randomized, double-blind phase 3 in resected ccRCC at increased risk of recurrence (N=1841). 🔹 Pembro 400 mg Q6W (~1 yr) + belzutifan 120 mg daily (≤54 wks) vs 🔹 Pembro + placebo Primary endpoint: Investigator-assessed DFS Key secondary: OS Median https://t.co/PHeqhGAQ31
Shreyas Kalantri, MD on AMBASSADOR
update from AMBASSADOR: adjuvant pembrolizumab improved DFS after surgery for high-risk MIBC, with no negative impact on overall HRQOL. Important data to support shared decision-making in the adjuvant setting. #ASCO26 https://t.co/CDWUHObquj
Shreyas Kalantri, MD on PEACE-3
Had a great time recording this Oncology Bytes episode with @ONCOassist reviewing key trials from @ASCO #GU26: • KEYNOTE-B15 in bladder cancer • Belzutifan trials in RCC • PEACE-3 in prostate cancer Always fun to discuss the studies shaping #GUOncology. https://t.co/eYoE91YDBQ
Shreyas Kalantri, MD’s Most-Engaged Posts in 2026
Their own 2026 posts that fellow physicians reposted most, quoted word for word.
Really enjoyed discussing @JackieAredoMD’s abstract during the @OncLive Fellows Forum panel. Key takeaway: in KRAS-mutated NSCLC, smoking history should not substitute for comprehensive molecular profiling. #ASCO26 #LCSM #FellowsForum https://t.co/jAftMVSYkt
Such a fun night meeting the 2026 GRACE Patient Education Ambassador crew and finally getting to connect in person. Excited for what’s ahead with @cancerGRACE. #ASCO26 https://t.co/Vi5kk2fM5C
Great to spend time with the @JCOOP_ASCO team at the @JCO_ASCO Editorial Fellowship reception during #ASCO26. Excited for the year ahead with the fellowship, and grateful to learn from such a thoughtful editorial team. https://t.co/hqn8dcx9Gg
Attending in person is just a different feeling. #PlenarySession #Daraxonrasib #ASCO26 https://t.co/9srqPyRkyC
Landed in Chicago and ready for #ASCO26. Always a special feeling to be here with the oncology community, reconnect with colleagues, learn from the science, and hopefully contribute a little along the way. Let’s go. @ASCO https://t.co/BXnZX7OTX4
Industry Payments
CMS Open Payments · 2025 general payments
$4,065 across 162 payments